![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 15, Issue 5, 2176-2188, May 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029;
Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201
Submitted July 18, 2003;
Revised December 22, 2003;
Accepted January 26, 2004
Monitoring Editor: Richard Assoian
Sprouty proteins are recently identified receptor tyrosine kinase (RTK) inhibitors potentially involved in many developmental processes. Here, we report that Sprouty proteins become tyrosine phosphorylated after growth factor treatment. We identified Tyr55 as a key residue for Sprouty2 phosphorylation and showed that phosphorylation was required for Sprouty2 to inhibit RTK signaling, because a mutant Sprouty2 lacking Tyr55 augmented signaling. We found that tyrosine phosphorylation of Sprouty2 affected neither its subcellular localization nor its interaction with Grb2, FRS2/SNT, or other Sprouty proteins. In contrast, Sprouty2 tyrosine phosphorylation was necessary for its binding to the Src homology 2-like domain of c-Cbl after fibroblast growth factor (FGF) stimulation. To determine whether c-Cbl was required for Sprouty2-dependent cellular events, Sprouty2 was introduced into c-Cbl-wild-type and -null fibroblasts. Sprouty2 efficiently inhibited FGF-induced phosphorylation of extracellular signal-regulated kinase 1/2 in c-Cbl-null fibroblasts, thus indicating that the FGF-dependent binding of c-Cbl to Sprouty2 was dispensable for its inhibitory activity. However, c-Cbl mediates polyubiquitylation/proteasomal degradation of Sprouty2 in response to FGF. Last, using Src-family pharmacological inhibitors and dominant-negative Src, we showed that a Src-like kinase was required for tyrosine phosphorylation of Sprouty2 by growth factors. Thus, these data highlight a novel negative and positive regulatory loop that allows for the controlled, homeostatic inhibition of RTK signaling.
Present address: INSERM U381, 3 Avenue Molière, 67000 Strasbourg, France.
Corresponding authors. E-mail addresses: jonathan.licht{at}mssm.edu or isabelle.gross{at}inserm.u-strasbg.fr.
This article has been cited by other articles:
|
|
 |
|
  A. Swat, I. Dolado, J. M. Rojas, and A. R. Nebreda Cell Density-Dependent Inhibition of Epidermal Growth Factor Receptor Signaling by p38{alpha} Mitogen-Activated Protein Kinase via Sprouty2 Downregulation Mol. Cell. Biol., June 15, 2009; 29(12): 3332 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Aranda, M. Alvarez, S. Turro, A. Laguna, and S. de la Luna Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A Mol. Cell. Biol., October 1, 2008; 28(19): 5899 - 5911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jaggi, M. A. Cabrita, A.-K. T. Perl, and G. Christofori Modulation of Endocrine Pancreas Development but not {beta}-Cell Carcinogenesis by Sprouty4 Mol. Cancer Res., March 1, 2008; 6(3): 468 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Edwin and T. B. Patel A Novel Role of Sprouty 2 in Regulating Cellular Apoptosis J. Biol. Chem., February 8, 2008; 283(6): 3181 - 3190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lito, B. D. Mets, S. Kleff, S. O'Reilly, V. M. Maher, and J. J. McCormick Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts J. Biol. Chem., January 25, 2008; 283(4): 2002 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chandramouli, C. Y. Yu, P. Yusoff, D.-H. Lao, H. F. Leong, K. Mizuno, and G. R. Guy Tesk1 Interacts with Spry2 to Abrogate Its Inhibition of ERK Phosphorylation Downstream of Receptor Tyrosine Kinase Signaling J. Biol. Chem., January 18, 2008; 283(3): 1679 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sutterluty, C.-E. Mayer, U. Setinek, J. Attems, S. Ovtcharov, M. Mikula, W. Mikulits, M. Micksche, and W. Berger Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms Mol. Cancer Res., May 1, 2007; 5(5): 509 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Lao, P. Yusoff, S. Chandramouli, R. J. Philp, C. W. Fong, R. A. Jackson, T. Y. Saw, C. Y. Yu, and G. R. Guy Direct Binding of PP2A to Sprouty2 and Phosphorylation Changes Are a Prerequisite for ERK Inhibition Downstream of Fibroblast Growth Factor Receptor Stimulation J. Biol. Chem., March 23, 2007; 282(12): 9117 - 9126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kajita, W. Ikeda, Y. Tamaru, and Y. Takai Regulation of platelet-derived growth factor-induced Ras signaling by poliovirus receptor Necl-5 and negative growth regulator Sprouty2 Genes Cells, March 1, 2007; 12(3): 345 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bundschu, U. Walter, and K. Schuh The VASP-Spred-Sprouty Domain Puzzle J. Biol. Chem., December 1, 2006; 281(48): 36477 - 36481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Lao, S. Chandramouli, P. Yusoff, C. W. Fong, T. Y. Saw, L. P. Tai, C. Y. Yu, H. F. Leong, and G. R. Guy A Src Homology 3-binding Sequence on the C Terminus of Sprouty2 Is Necessary for Inhibition of the Ras/ERK Pathway Downstream of Fibroblast Growth Factor Receptor Stimulation J. Biol. Chem., October 6, 2006; 281(40): 29993 - 30000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cabrita, F. Jaggi, S. P. Widjaja, and G. Christofori A Functional Interaction between Sprouty Proteins and Caveolin-1 J. Biol. Chem., September 29, 2006; 281(39): 29201 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chi, P. Itaranta, S. Zhang, and S. Vainio Sprouty2 Is Involved in Male Sex Organogenesis by Controlling Fibroblast Growth Factor 9-Induced Mesonephric Cell Migration to the Developing Testis Endocrinology, August 1, 2006; 147(8): 3777 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choi, S.-Y. Cho, R. H. Schwartz, and K. Choi Dual Effects of Sprouty1 on TCR Signaling Depending on the Differentiation State of the T Cell J. Immunol., May 15, 2006; 176(10): 6034 - 6045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Jarvis, S. J. Toering, M. A. Simon, M. A. Krasnow, and R. K. Smith-Bolton Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases Development, March 15, 2006; 133(6): 1133 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. DaSilva, L. Xu, H. J. Kim, W. T. Miller, and D. Bar-Sagi Regulation of sprouty stability by mnk1-dependent phosphorylation. Mol. Cell. Biol., March 1, 2006; 26(5): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. de Alvaro, N. Martinez, J. M. Rojas, and M. Lorenzo Sprouty-2 Overexpression in C2C12 Cells Confers Myogenic Differentiation Properties in the Presence of FGF2 Mol. Biol. Cell, September 1, 2005; 16(9): 4454 - 4461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rubin, Y. Zwang, N. Vaisman, D. Ron, and Y. Yarden Phosphorylation of Carboxyl-terminal Tyrosines Modulates the Specificity of Sprouty-2 Inhibition of Different Signaling Pathways J. Biol. Chem., March 11, 2005; 280(10): 9735 - 9744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, V. G. Brunton, H. R. Burgar, L. M. Wheldon, and J. K. Heath FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity J. Cell Sci., December 1, 2004; 117(25): 6007 - 6017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Torii, K. Nakayama, T. Yamamoto, and E. Nishida Regulatory Mechanisms and Function of ERK MAP Kinases J. Biochem., November 1, 2004; 136(5): 557 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kwabi-Addo, J. Wang, H. Erdem, A. Vaid, P. Castro, G. Ayala, and M. Ittmann The Expression of Sprouty1, an Inhibitor of Fibroblast Growth Factor Signal Transduction, Is Decreased in Human Prostate Cancer Cancer Res., July 15, 2004; 64(14): 4728 - 4735. [Abstract] [Full Text] [PDF]
|
|
